Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 44


Data Analysis for High-Throughput RNAi Screening.

Azorsa DO, Turnidge MA, Arora S.

Methods Mol Biol. 2016;1470:247-60. doi: 10.1007/978-1-4939-6337-9_19.


Optimization of Transfection Conditions for siRNA Screening.

Montoya JJ, Azorsa DO.

Methods Mol Biol. 2016;1470:15-24. doi: 10.1007/978-1-4939-6337-9_2.


Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma.

Bogen D, Wei JS, Azorsa DO, Ormanoglu P, Buehler E, Guha R, Keller JM, Mathews Griner LA, Ferrer M, Song YK, Liao H, Mendoza A, Gryder BE, Sindri S, He J, Wen X, Zhang S, Shern JF, Yohe ME, Taschner-Mandl S, Shohet JM, Thomas CJ, Martin SE, Ambros PF, Khan J.

Oncotarget. 2015 Nov 3;6(34):35247-62. doi: 10.18632/oncotarget.6208.


BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX, Mantei J, Ahmann G, Gonzales IM, Choudhary A, Valdez R, Camoriano J, Fauble V, Tiedemann RE, Qiu YH, Coombes KR, Cardone M, Braggio E, Yin H, Azorsa DO, Mesa RA, Stewart AK, Tibes R.

Leukemia. 2014 Aug;28(8):1657-65. doi: 10.1038/leu.2014.44.


High-throughput RNAi screening for the identification of novel targets.

Henderson MC, Azorsa DO.

Methods Mol Biol. 2013;986:89-95. doi: 10.1007/978-1-62703-311-4_6.


Negative regulation of NF-κB by the ING4 tumor suppressor in breast cancer.

Byron SA, Min E, Thal TS, Hostetter G, Watanabe AT, Azorsa DO, Little TH, Tapia C, Kim S.

PLoS One. 2012;7(10):e46823. doi: 10.1371/journal.pone.0046823.


BIRC5 expression is a poor prognostic marker in Ewing sarcoma.

Hingorani P, Dickman P, Garcia-Filion P, White-Collins A, Kolb EA, Azorsa DO.

Pediatr Blood Cancer. 2013 Jan;60(1):35-40. doi: 10.1002/pbc.24290.


Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1: a paradigm shift that impacts current therapeutic strategies.

Marlow LA, von Roemeling CA, Cooper SJ, Zhang Y, Rohl SD, Arora S, Gonzales IM, Azorsa DO, Reddi HV, Tun HW, Döppler HR, Storz P, Smallridge RC, Copland JA.

J Cell Sci. 2012 Sep 15;125(Pt 18):4253-63. doi: 10.1242/jcs.097428.


The genomic and proteomic content of cancer cell-derived exosomes.

Henderson MC, Azorsa DO.

Front Oncol. 2012 Apr 17;2:38. doi: 10.3389/fonc.2012.00038.


RNAi screening of the kinome with cytarabine in leukemias.

Tibes R, Bogenberger JM, Chaudhuri L, Hagelstrom RT, Chow D, Buechel ME, Gonzales IM, Demuth T, Slack J, Mesa RA, Braggio E, Yin HH, Arora S, Azorsa DO.

Blood. 2012 Mar 22;119(12):2863-72. doi: 10.1182/blood-2011-07-367557.


High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells.

Henderson MC, Gonzales IM, Arora S, Choudhary A, Trent JM, Von Hoff DD, Mousses S, Azorsa DO.

Mol Cancer Res. 2011 Jun;9(6):724-32. doi: 10.1158/1541-7786.MCR-10-0436.


NCI60 cancer cell line panel data and RNAi analysis help identify EAF2 as a modulator of simvastatin and lovastatin response in HCT-116 cells.

Savas S, Azorsa DO, Jarjanazi H, Ibrahim-Zada I, Gonzales IM, Arora S, Henderson MC, Choi YH, Briollais L, Ozcelik H, Tuzmen S.

PLoS One. 2011 Apr 4;6(4):e18306. doi: 10.1371/journal.pone.0018306.


Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer.

Ruiz C, Holz DR, Oeggerli M, Schneider S, Gonzales IM, Kiefer JM, Zellweger T, Bachmann A, Koivisto PA, Helin HJ, Mousses S, Barrett MT, Azorsa DO, Bubendorf L.

J Pathol. 2011 Mar;223(4):543-52. doi: 10.1002/path.2828.


Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target.

Marlow LA, D'Innocenzi J, Zhang Y, Rohl SD, Cooper SJ, Sebo T, Grant C, McIver B, Kasperbauer JL, Wadsworth JT, Casler JD, Kennedy PW, Highsmith WE, Clark O, Milosevic D, Netzel B, Cradic K, Arora S, Beaudry C, Grebe SK, Silverberg ML, Azorsa DO, Smallridge RC, Copland JA.

J Clin Endocrinol Metab. 2010 Dec;95(12):5338-47. doi: 10.1210/jc.2010-1421. Erratum in: J Clin Endocrinol Metab. 2013 Oct;98(10):4213. J Clin Endocrinol Metab. 2013 Nov;98(11):4546.


RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells.

Arora S, Bisanz KM, Peralta LA, Basu GD, Choudhary A, Tibes R, Azorsa DO.

Gynecol Oncol. 2010 Sep;118(3):220-7.


RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma.

Arora S, Gonzales IM, Hagelstrom RT, Beaudry C, Choudhary A, Sima C, Tibes R, Mousses S, Azorsa DO.

Mol Cancer. 2010 Aug 18;9:218. doi: 10.1186/1476-4598-9-218.


Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer.

Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO, Yang F, Pineda M, Helman LJ, Meltzer PS.

Cancer Res. 2010 Aug 15;70(16):6497-508. doi: 10.1158/0008-5472.CAN-10-0582.


A high-content RNAi-screening assay to identify modulators of cholesterol accumulation in Niemann-Pick type C cells.

Arora S, Beaudry C, Bisanz KM, Sima C, Kiefer JA, Azorsa DO.

Assay Drug Dev Technol. 2010 Jun;8(3):295-320. doi: 10.1089/adt.2009.0240.


Chemogenomic analysis identifies Macbecin II as a compound specific for SMAD4-negative colon cancer cells.

Kaiser C, Meurice N, Gonzales IM, Arora S, Beaudry C, Bisanz KM, Robeson AC, Petit J, Azorsa DO.

Chem Biol Drug Des. 2010 Apr;75(4):360-8. doi: 10.1111/j.1747-0285.2010.00949.x.


High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation.

Azorsa DO, Robeson RH, Frost D, Meec hoovet B, Brautigam GR, Dickey C, Beaudry C, Basu GD, Holz DR, Hernandez JA, Bisanz KM, Gwinn L, Grover A, Rogers J, Reiman EM, Hutton M, Stephan DA, Mousses S, Dunckley T.

BMC Genomics. 2010 Jan 12;11:25. doi: 10.1186/1471-2164-11-25.

Items per page

Supplemental Content

Loading ...
Support Center